Investment in health and medical research generates significant returns both in terms of health benefits - longevity and increased quality of life for Australians; and economic benefits through increased knowledge-based jobs and economic activity.
At the end of 2003, the Federal Government established a committee to review funding for health and medical research in Australia.
John Grant, chairman of biotechnology companies Biota and Ambri, headed the review. Peter Wills, who chaired the 1998 'Health and Medical Research Strategic Review', was a strategic adviser.
Pacific Strategy Partners acted as secretariat to the review, drawing on the experience of our staff who also worked in the 1998 'Health and Medical Research Strategic Review'. The 1998 review prompted the Government to double NHMRC funding for health and medical research.
Over five years from 1999 the Government had invested an extra $614 million in the NHMRC. It was now time to review the impact of that investment and look to the future needs of health and medical research.
The findings of the latest review were released on December 9th, 2004. Some links related to this review are given below.
- FINAL REPORT - Department of Health and Ageing - Final Report: Investment Review of Health and Medical Research 2004 (PDF)
- PRESS RELEASE - IRHMR Committee - IRHMR Press Release (9/12/2004) (DOC)
- EXECUTIVE SUMMARY - Department of Health and Ageing - Executive Summary: Investment Review of Health and Medical Research 2004 (PDF)